Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oman seeks funds for BMT (bone marrow transplant) unit expansion:

This article was originally published in Clinica

Executive Summary

The Sultan Qaboos University Hospital (SQUH) in Oman is requesting funds to finance its expansion after a dramatic increase in the number of patients in need of bone marrow transplant (BMT) operations. Expansion is urgently needed, SQUH claims, because at present patients suffering from thalassaemia must wait up to three years for a transplant. The department of haematology at the university has recently carried out its 50th BMT operation and has recorded results "comparable with the best bone marrow transplant centres in the West at a fraction of the cost", reports the Oman Daily Observer. The cost of BMT in the UK and US ranges from OR60,000-100,000 ($156,000-260,000). In Oman, it is only OR20,000, including the cost of follow-up treatment for two years after the operation.

You may also be interested in...

WHO No-Go Not A Swan Song For Remdesivir In India?

The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things. 

QUOTED. 30 November 2020. David Hoffmeister.

A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts